Related Experiment Video
Updated: May 7, 2026
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
Integrating advances in insulin into clinical practice. Introduction
1Department of Family Medicine, University of North Carolina Chapel Hill, North Carolina, Executive Vice President for Education, Primary Care Education Consortium,mCharlotte, NC, USA.
The Journal of Family Practice
|October 2, 2013
Summary
Diabetes mellitus prevalence is increasing in the US, with more people diagnosed despite reductions in smoking and high blood pressure. Obesity and dysglycemia rates are also rising.
Area of Science:
- Public Health
- Epidemiology
- Metabolic Diseases
Background:
- The United States has seen a continuous rise in diabetes mellitus prevalence, from 17.9 million (2003-2006) to 18.8 million (2010).
- Concurrently, there have been observed decreases in smoking, high cholesterol, and high blood pressure between 1988 and 2008.
Discussion:
- Despite public health efforts reducing risk factors like smoking and hypertension, the incidence of dysglycemia and obesity has increased.
- This indicates a complex interplay of factors contributing to the metabolic health crisis.
Key Insights:
- Diabetes mellitus prevalence continues to escalate in the US population.
- Obesity and dysglycemia are increasing, even as other traditional cardiovascular risk factors decline.
Outlook:
- Further research is needed to understand the drivers behind the rising obesity and dysglycemia rates.
- Public health strategies may need re-evaluation to address these growing metabolic challenges effectively.
Related Concept Videos
01:25Insulin: Biosynthesis, Chemistry, and Preparation
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...
01:27Insulin Formulations: Types and Delivery
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into rapid-acting...
Short-acting insulins are divided into rapid-acting...
01:16Insulin: Dosing Regimen and Adverse Effects
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
01:15Diabetes: Management and Pharmacotherapy
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
01:30Production of Pharmaceuticals
Industrial insulin production uses genetically engineered E. coli expressing a proinsulin gene controlled by a tryptophan promoter and containing a methionine linker for later cleavage. The cells also carry ampicillin resistance for selective growth. Seed cultures are stored at −80 °C and production begins by thawing a small amount to inoculate starter cultures, which are progressively scaled to a 50,000-L bioreactor. In the bioreactor, E. coli grow in nutrient-rich media under sterile, tightly...
01:26Diabetes Mellitus: Introduction
Diabetes mellitus consists of chronic metabolic disorders characterized by persistent hyperglycemia. This elevated blood glucose results from defects in insulin secretion, impaired insulin action, or both. Insulin, produced by pancreatic β-cells, is essential for maintaining glucose homeostasis by facilitating cellular glucose uptake for energy or storage. Disruptions in insulin production or function lead to glucose accumulation in the bloodstream, causing the clinical features and long-term...